Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.

Still, the overall survival analysis outcome event has notyet reached more than 80%, which is 59.83%, which may be one of the reasons whysome variables in OS analysis (e.g, declared versus non-declared regions, classicalversus rare mutations, single versus compound mutations, and subgroup analysis)showed a trend of difference in values but did not reach statistical difference.Nevertheless, our study showed expected results that have not been reported before.We will continue to follow up and unveil the findings ofOS maturity data as soon aspossible.

also in 53,322 other papers